Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.

S I Nihtyanova1, G M Brough, C M Black

  • 1Centre for Rheumatology, Royal Free Hospital, London, UK.

Rheumatology (Oxford, England)
|August 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access.

Journal of medical economics·2026
Same author

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

Frontiers in oncology·2025
Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

The critical need for patient-reported outcome measures to assess the severity and impact of systemic sclerosis.

The British journal of dermatology·2021
Same author

In vitro effects of macrophages on orthopaedic implant alloys and local release of metallic alloy components.

The bone & joint journal·2020
Same author

The patient knows best: a new self-reported outcome measure for systemic sclerosis.

The British journal of dermatology·2020

Mycophenolate mofetil (MMF) is well-tolerated and effective for diffuse cutaneous systemic sclerosis (dcSSc), showing reduced pulmonary fibrosis and improved survival compared to other immunosuppressants.

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Diffuse cutaneous systemic sclerosis (dcSSc) is a severe autoimmune disease.
  • Limited treatment options exist for dcSSc, necessitating evaluation of novel therapies.

Purpose of the Study:

  • To assess the efficacy and tolerability of mycophenolate mofetil (MMF) in dcSSc patients.
  • To compare MMF treatment outcomes with other immunosuppressive drugs in dcSSc.

Main Methods:

  • Retrospective review of 109 MMF-treated patients and 63 controls.
  • Data collected over a 5-year period, including adverse events and clinical outcomes.

Main Results:

  • MMF was well-tolerated, with most adverse events being gastrointestinal or infections.

Related Experiment Videos

  • MMF treatment showed significantly lower rates of pulmonary fibrosis and improved 5-year survival.
  • No significant differences were observed in skin score or forced vital capacity (FVC) changes.

    • Conclusions:

    • MMF is a safe and effective treatment option for dcSSc, comparable to existing therapies.
    • Further prospective trials are warranted to confirm MMF's benefits in dcSSc.